Gilder Gagnon Howe & Co. LLC Boosts Stake in BridgeBio Pharma, Inc. $BBIO

by · The Cerbat Gem

Gilder Gagnon Howe & Co. LLC grew its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 280.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 465,401 shares of the company’s stock after acquiring an additional 343,158 shares during the period. Gilder Gagnon Howe & Co. LLC owned about 0.24% of BridgeBio Pharma worth $20,096,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Steward Partners Investment Advisory LLC grew its stake in BridgeBio Pharma by 22.3% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 1,250 shares of the company’s stock valued at $54,000 after purchasing an additional 228 shares in the last quarter. Gabelli Funds LLC boosted its stake in shares of BridgeBio Pharma by 0.3% during the 2nd quarter. Gabelli Funds LLC now owns 73,750 shares of the company’s stock valued at $3,185,000 after buying an additional 250 shares during the last quarter. First Bank & Trust grew its position in shares of BridgeBio Pharma by 3.9% during the second quarter. First Bank & Trust now owns 8,822 shares of the company’s stock worth $381,000 after buying an additional 329 shares in the last quarter. Main Management ETF Advisors LLC increased its stake in shares of BridgeBio Pharma by 1.7% in the second quarter. Main Management ETF Advisors LLC now owns 22,723 shares of the company’s stock worth $981,000 after buying an additional 372 shares during the last quarter. Finally, Bank of Montreal Can raised its holdings in BridgeBio Pharma by 6.0% in the second quarter. Bank of Montreal Can now owns 9,865 shares of the company’s stock valued at $426,000 after acquiring an additional 556 shares in the last quarter. Institutional investors and hedge funds own 99.85% of the company’s stock.

Insider Transactions at BridgeBio Pharma

In other news, Director Andrew Lo sold 55,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $65.69, for a total value of $3,612,950.00. Following the completion of the sale, the director directly owned 50,583 shares of the company’s stock, valued at approximately $3,322,797.27. This represents a 52.09% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ronald J. Daniels sold 61,031 shares of the company’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $63.72, for a total transaction of $3,888,895.32. Following the completion of the sale, the director directly owned 16,991 shares of the company’s stock, valued at $1,082,666.52. The trade was a 78.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 557,204 shares of company stock worth $36,561,480 over the last ninety days. Insiders own 18.20% of the company’s stock.

BridgeBio Pharma Stock Up 1.5%

Shares of BBIO stock opened at $75.15 on Friday. The company has a market cap of $14.48 billion, a P/E ratio of -17.98 and a beta of 1.26. The business has a 50 day moving average of $64.09 and a two-hundred day moving average of $52.55. BridgeBio Pharma, Inc. has a 52 week low of $25.34 and a 52 week high of $75.24.

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last announced its quarterly earnings results on Wednesday, October 29th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.07). The firm had revenue of $120.70 million for the quarter, compared to the consensus estimate of $107.71 million. The business’s revenue for the quarter was up 4318.0% on a year-over-year basis. During the same period last year, the business posted ($0.86) earnings per share. Analysts expect that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BBIO has been the subject of several research analyst reports. Wells Fargo & Company boosted their target price on shares of BridgeBio Pharma from $76.00 to $84.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Evercore ISI reiterated an “outperform” rating on shares of BridgeBio Pharma in a research note on Monday, October 27th. Cantor Fitzgerald upped their price objective on BridgeBio Pharma from $100.00 to $110.00 and gave the company an “overweight” rating in a research note on Thursday, October 30th. Sanford C. Bernstein began coverage on BridgeBio Pharma in a report on Thursday. They set an “outperform” rating and a $94.00 target price on the stock. Finally, JPMorgan Chase & Co. boosted their price target on BridgeBio Pharma from $76.00 to $77.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Twenty-one investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $75.35.

Check Out Our Latest Research Report on BridgeBio Pharma

BridgeBio Pharma Profile

(Free Report)

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.

Read More

Want to see what other hedge funds are holding BBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report).